

IMMUNE CELLS AND METASTASIS



Group Leader
Seth Coffelt

Research Scientists
Sarah Edwards¹
Toshiyasu Suzuki^{2,3}

Scientific Officer
Anna Kilbey¹

Graduate Students
Liam Hayman^{4,10}
Mark Lawrence⁵
Sarah-Jane Remak^{1,6}

Visiting Scientist
Erin Morris⁷

Interns
Shruthi Arumugam⁸
Rhona Millar⁸
Robert Wiesheu⁹

¹CRUK Glasgow Centre
²Naito Foundation of Japan
³Marie Skłodowska-Curie
Actions Fellowship
⁴Medical Research Council
⁵Pancreatic Cancer UK Future
Leaders Academy
⁶William Forrest Charitable
Trust PhD Research Fund
⁷Department Chair of Biology
& Chemistry, Baker University,
Baldwin City, Kansas, USA
⁸University of Glasgow
⁹Ludwig Maximilian University,
Munich, Germany
¹⁰Co-supervised by Joanne
Edwards and Antonia Roseweir

Our lab focuses on the regulation and function of $\gamma\delta$ T cells in tumour progression, using genetically engineered mouse models of cancer. $\gamma\delta$ T cells are a unique cell population – they are small in number but have major influences on neighboring cells during immunity. We aim to understand how $\gamma\delta$ T cells behave in tumour-bearing mice, specifically in pre-metastatic organs, and to uncover regulatory pathways governing these cells that may be manipulated to counteract metastasis formation. Our research is centered on three main cancer types: breast, colon and pancreas.

$\gamma\delta$ T cells in breast cancer

A subset of $\gamma\delta$ T cells promotes mammary tumour metastasis through expression of the cytokine IL-17 (Coffelt *et al.*, Nature 2015; 522: 345–8). Last year, we found that this subset of IL-17-producing $\gamma\delta$ T cells expresses the receptor NKG2D – a molecule more commonly associated with natural killer (NK) cells and cancer cell killing. Our work to understand the function of this killing receptor on pro-metastatic $\gamma\delta$ T cells continued into 2018. We found that NKG2D-expressing $\gamma\delta$ T cells are enriched in lung tissue, when compared to lymph nodes, spleen, liver or thymus. These data suggest that they may have an important role in metastasis, since the lung is the primary site of cancer cell dissemination in mice. Interestingly, NKG2D-expressing $\gamma\delta$ T cells are not present in lungs after birth, but arise sometime after weaning. We are currently exploring the idea that NKG2D is involved in regulation of IL-17 expression in $\gamma\delta$ T cells. We have profiled various cell populations in the lung to determine where the ligands for NKG2D are expressed and how mammary tumours affect ligand expression. This analysis uncovered monocytes as the main producers of NKG2D ligands, so we will investigate the relationship between monocytes and $\gamma\delta$ T cells over the coming year. We have secured funding from Breast Cancer Now for this project. All our work in breast cancer is done in collaboration with Karen Blyth and her team.

To gain a better understanding of $\gamma\delta$ T cell heterogeneity in the lung, we have performed single-cell sequencing on these cells in collaboration with Kristina Kirschner (University of Glasgow) and Nizar Batada (University of

Edinburgh). An unbiased transcriptional analysis of 1000s of individual cells revealed two major clusters of $\gamma\delta$ T cells in accordance with published literature that largely segregate on cytotoxic molecules (Fig. 1a). Within these two major clusters, we identified populations expressing T cell receptor signalling molecules, co-stimulatory molecules, T cell checkpoint inhibitors, lymph node trafficking molecules, NK cell markers, cytokines (such as IL-17) and cytokine receptors, as well as genes involved in NOTCH signaling. This in-depth analysis of $\gamma\delta$ T cells at the single-cell level provides further insight into $\gamma\delta$ T cell biology in homeostasis and cancer.

$\gamma\delta$ T cells in colorectal cancer

In collaboration with Owen Sansom and his lab, we are investigating the role of $\gamma\delta$ T cells in various mouse models that recapitulate distinct molecular subtypes of colon cancer. We have found that the absence of $\gamma\delta$ T cells fails to influence tumour growth and survival in models driven by loss of the tumour suppressor Apc. At



Seth Coffelt giving a tour of the labs to Rebecca Scott, who underwent treatment for ovarian cancer in 2017. Photo credit: Steve Welsh

Figure 1
 $\gamma\delta$ T cells in mammary, pancreatic and colon cancers
(a) $\gamma\delta$ T cells sorted from lungs of wild-type mice and analysed by single-cell sequencing. Analysis shows that two main populations of $\gamma\delta$ T cells reside in the lungs under homeostatic conditions.
(b) $\gamma\delta$ T cell abundance in microsatellite unstable tumours of the gut as determined by RNAscope for the *Trdc* transcript.
(c) Neutrophil counts in blood of wild-type (WT) mice, tumour-bearing KPC mice, $\gamma\delta$ T cell-deficient (*Tcrd*^{-/-}) mice and tumour-bearing, $\gamma\delta$ T cell-deficient KPC mice. Each dot represents one mouse. P value was determined by one-way ANOVA.

the same time, we profiled the phenotype of $\gamma\delta$ T cells in two other models of colorectal carcinoma, which indicate that $\gamma\delta$ T cells may be important. We found that IL-17-producing $\gamma\delta$ T cells are increased in the metastatic *Villin-Cre;Kras^{G12D};Trp53^{fl/fl};Nid1^{fl/fl}* model and, in a similar fashion to our observations in metastatic mammary tumour models, we find that the increase in IL-17-producing $\gamma\delta$ T cells occurs in visceral organs in addition to the primary tumour. Over the next year, we will determine whether IL-17-producing $\gamma\delta$ T cells play a role in primary tumour growth or metastasis formation in this model. We have also been using a model of microsatellite instability, which has provided some surprising results. Unlike any other cancer model we have profiled, $\gamma\delta$ T cells make up a large proportion of infiltrating T cells in microsatellite unstable tumours (Fig. 1b). We have shown that these $\gamma\delta$ T cells produce IL-17 and that their infiltration correlates with neutrophil influx. In the future, we aim to determine whether they are required for tumour growth and the mechanisms by which they are recruited to tumours.

$\gamma\delta$ T cells in pancreatic cancer

Using the *Kras^{G12D};Trp53^{fl/fl};Pdx1-Cre* (KPC) model, we are exploring the ability of $\gamma\delta$ T cells to influence pancreatic ductal adenocarcinoma (PDAC) and liver metastasis. This work is done in collaboration with Jen Morton. We crossed the KPC model with $\gamma\delta$ T cell-deficient (*Tcrd*^{-/-}) mice and measured neutrophils in the circulation of these mice. In contrast to our previous observations in mammary tumour-bearing mice, we found that neutrophils were unaffected by the absence of $\gamma\delta$ T cells (Fig. 1c), indicating that $\gamma\delta$ T cells are not required for neutrophil expansion in the presence of PDAC. When we profiled conventional T cells and NK cells in livers of tumour-bearing mice, however, we noticed that NK cell activity was increased in $\gamma\delta$ T cell-deficient mice, while T cells remain unchanged. These data suggest that $\gamma\delta$ T cells may communicate with NK cells to suppress their function in liver tissue. Over the next year, we will examine the crosstalk between NK cells and $\gamma\delta$ T cells and measure any impact on pancreatic cancer metastasis.

Publications listed on page 84

